Amwell AI Visibility Market Strategy Report - Online Doctors

Answer Capsule

Amwell holds 23.72% valid recommendation coverage in the October 2026 Online Doctors benchmark, placing it sixth of ten tracked brands. The brand appears in 38.05% of qualified AI answers but converts that presence into a valid recommendation in fewer than one in four, a gap of 14.33 points between raw mention presence and recommendation coverage. Its clearest win is a 14.16% top-three rate that more than doubled from 7.8% in July 2026, while its clearest weakness is a rank-one rate of 0.53%, the lowest among the top six brands. The biggest opportunity sits in converting shortlist appearances into first-position recommendations, where Teladoc Health holds a 27.96% rank-one rate against Amwell's 0.53%.

Who This Report Is For

This report is written for Amwell's marketing, growth, and communications leadership, and for enterprise telehealth buyers evaluating how the brand is positioned when AI systems answer high-intent online doctor questions.

Report Card

Executive Summary

Amwell is visible in the Online Doctors category but under-recommended. The October 2026 LLM Authority Index benchmark recorded 215 mentions of Amwell across 565 qualified observations, a raw mention presence rate of 38.05%. Of those, 134 converted into valid recommendations, producing a valid recommendation coverage rate of 23.72%. The 14.33-point gap between presence and recommendation coverage is the central story: AI systems know the brand, but they do not consistently place it on the buyer shortlist.

The framing layer is clean. Amwell recorded 142 positive mentions, 73 neutral mentions, and zero negative mentions, producing a net sentiment score of 0.6605. That is the lowest net sentiment score among the six brands with meaningful coverage, which suggests the brand is more often referenced as context than praised as a preferred option.

The strongest cluster is C01, Best Online Doctors and Top Telehealth Services, the only cluster with sufficient qualified observations in the October 2026 series. Amwell's C01 top-three rate is 14.16%, its rank-one rate is 0.53%, and its average recommended rank is 3.1570. The Pricing and Value cluster and the Multi-Brand Comparison cluster both returned no qualified observations, so the benchmark cannot yet answer how Amwell performs on cost, insurance, or head-to-head comparison prompts.

The strongest platform signal for Amwell is Perplexity, where the brand recorded a 50.0% valid recommendation coverage rate and a 44.12% top-three rate. The weakest platform signal among platforms with meaningful volume is Google AI Mode, where Amwell's valid recommendation coverage was 17.90% and its top-three rate was 8.64%. Google AI Overviews carried the largest observation base at 166 and returned Amwell an 18.07% coverage rate.

The clearest competitive gap is placement, not presence. Teladoc Health recorded a 40.18% top-three rate and a 27.96% rank-one rate in October 2026, while Doctor on Demand recorded a 37.70% top-three rate and a 13.98% rank-one rate. Amwell's top-three rate of 14.16% is roughly a third of Teladoc Health's, and its rank-one rate of 0.53% is roughly a fiftieth. The brand is in the room but rarely at the front of it.

Amwell did post a significant month-over-month coverage gain, rising to 23.7% in October 2026 from 18.8% in September 2026, which the benchmark flagged as beyond normal variation. That move is real but modest against the category leaders, and the baseline-to-current gain of 3.0 points from July 2026 remains inside normal variation.

What Amwell Is Winning

Questions This Section Answers

• How much did Amwell's top-three recommendation rate improve since July 2026?
• Which platform produced Amwell's strongest recommendation signal in October 2026?
• Did Amwell's month-over-month coverage gain represent a new peak or a recovery?

Amwell's clearest win is the top-three rate expansion. The brand's recommended top-three rate rose from 7.8% in July 2026 to 14.16% in October 2026, a 6.36-point gain. That is the second-largest top-three improvement among the tracked brands behind Doctor on Demand and Teladoc Health, and it shows the brand is being pulled into more shortlists than it was at the start of the series.

The second win is Perplexity. Amwell recorded a 50.0% valid recommendation coverage rate on Perplexity across 34 observations, with a 44.12% top-three rate and a 2.7647 average recommended rank. That is the strongest platform-level recommendation signal in Amwell's October 2026 data and the only platform where the brand approaches the category leaders.

The third win is the absence of negative framing. Amwell recorded zero negative mentions across 215 total mentions in October 2026. The brand is not being cautioned against, and the public evidence layer is not producing reputational drag in AI answers.

The fourth win is the month-over-month rebound. Amwell rose 4.9 points from September 2026 to October 2026, a move the benchmark flagged as significant. September 2026 was the series low at 18.8%, so the October 2026 reading represents a recovery rather than a new peak.

These are real but narrow wins. Amwell does not hold a category lead on any primary metric, and its rank-one rate of 0.53% is the weakest among the top six brands by a wide margin.

Where Amwell Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does Amwell convert fewer AI mentions into valid recommendations than Doctor on Demand?
• Which platforms carry Amwell's weakest first-position recommendation rates despite high observation volume?
• What does Amwell's absence from the top cited domains suggest about its owned content?

The clearest gap is recommendation conversion. Amwell appears in 38.05% of qualified AI answers but receives a valid recommendation in only 23.72%. That means roughly 38 of every 100 answers that mention Amwell do not convert the mention into a shortlist placement. Doctor on Demand, by contrast, appears in 66.02% of answers and converts 48.32% into valid recommendations, a conversion ratio of 73%. Amwell's conversion ratio is 62%.

The second gap is first-position placement. Amwell recorded a rank-one rate of 0.53% in October 2026, meaning the brand was the first recommendation in roughly 3 of 565 qualified observations. Teladoc Health recorded a rank-one rate of 27.96%, Doctor on Demand 13.98%, Sesame 12.92%, and plushcare 6.73%. Amwell is being shortlisted but almost never chosen first.

The third gap is platform concentration. Amwell's recommendation strength is heavily concentrated on Perplexity, which carried only 34 observations. On Google AI Overviews, which carried 166 observations, Amwell's coverage rate was 18.07% and its rank-one rate was 0.60%. On Google AI Mode, which carried 162 observations, Amwell's coverage rate was 17.90% and its rank-one rate was 0.62%. The platforms with the largest observation bases are the platforms where Amwell is weakest.

The fourth gap is the absence of qualified observations in the Pricing and Value and Multi-Brand Comparison clusters. The benchmark recorded zero qualified observations in both clusters across the full series, so Amwell's performance on cost, insurance, and head-to-head comparison prompts is unmeasured. That is a category-level limitation, not an Amwell-specific one, but it means the brand cannot yet be assessed on the prompt types closest to a purchase decision.

The fifth gap is the citation layer. Amwell's domain does not appear in the top 10 cited domains for October 2026. The top cited domains include doctorondemand.com at number one with 324 citations, sesamecare.com at number three with 227 citations, teladochealth.com at number five with 197 citations, and plushcare.com at number six with 170 citations. Third-party sources including goodrx.com, healthline.com, walgreens.com, and helloklarity.com also feature prominently. Amwell's absence from the top cited domains suggests the brand's owned content is not the primary source AI systems retrieve when forming online doctor recommendations.

Biggest Opportunity

Questions This Section Answers

• Why is first-position placement on Google AI Overviews and AI Mode Amwell's biggest opportunity?
• How large is Amwell's rank-one gap against Teladoc Health on the two highest-volume platforms?

The single biggest opportunity for Amwell is converting shortlist appearances into first-position recommendations on Google AI Overviews and Google AI Mode. Those two platforms carried 328 of the 565 qualified observations in October 2026, and Amwell's rank-one rate on both sits below 1%. Teladoc Health recorded a 30.12% rank-one rate on Google AI Overviews and a 27.78% rank-one rate on Google AI Mode across the same observation base. The gap is not about being mentioned; it is about being named first when AI systems answer high-intent online doctor questions. Closing even a fraction of that gap on the two highest-volume platforms would move Amwell's overall rank-one rate more than any other single change.

Competitive Landscape

Questions This Section Answers

• Where does Amwell sit in the October 2026 Online Doctors recommendation standings?
• Which competitors separate the top tier from Amwell's second-tier position?

Sesame, Doctor on Demand, and Teladoc Health hold the strongest recommendation-stage positions in the October 2026 Online Doctors benchmark. Amwell sits in the second tier, behind the top three and ahead of MDLive, with a top-three rate of 14.16% and a rank-one rate of 0.53%.

Average recommended rank covers rank-eligible recommendations only.

Amwell ranks sixth on top-three rate and sixth on rank-one rate, with an average recommended rank of 3.1570 that sits between MDLive at 3.1203 and LiveHealth Online at 3.0000. The table shows a clear separation between the top four brands, all above 27% top-three rate, and the remaining six, all below 20%. Amwell's position within that second tier is defined by a top-three rate that is competitive with MDLive but a rank-one rate that is not.

Prompt Evidence

Perplexity / Best Online Doctors and Top Telehealth Services Prompt: "Which online doctors are legit?" Result: Amwell appeared in the recommendation set with a top-three placement, contributing to the brand's 44.12% Perplexity top-three rate.

Google AI Mode / Best Online Doctors and Top Telehealth Services Prompt: "online doctors" Result: Amwell was mentioned but placed outside the top three in most responses, consistent with the brand's 8.64% Google AI Mode top-three rate.

Google AI Overviews / Best Online Doctors and Top Telehealth Services Prompt: "telemedicine services" Result: Amwell appeared as a reference option rather than a first-position recommendation, with a 0.60% rank-one rate across the platform.

ChatGPT / Best Online Doctors and Top Telehealth Services Prompt: "Can I speak to a doctor for free online?" Result: Amwell was mentioned in 70.73% of ChatGPT responses but received a rank-one placement in none of them, reflecting the brand's 0.0% ChatGPT rank-one rate.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map Amwell's prompt-level recommendation outcomes across all six tracked platforms, with particular focus on Google AI Overviews and Google AI Mode, where the brand's rank-one rate sits below 1%.

Phase 2: Recommendation Readiness Plan Identify the specific prompt types and answer structures where Amwell is shortlisted but not placed first, and prioritize the highest-volume gaps for correction.

Phase 3: Owned Answer Layer Buildout Strengthen Amwell's owned content so that AI systems retrieve clear, structured, first-position-friendly answers on the online doctor questions that drive the category.

Phase 4: Citation and Authority Layer Development Address Amwell's absence from the top cited domains by building the third-party and owned source footprint that AI systems appear to draw on when forming recommendations.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Amwell's top-three rate, rank-one rate, and platform-level coverage month over month to confirm whether placement gains hold beyond a single reporting period.

Why This Matters

AI systems are now forming the buyer shortlist for online doctor services. Amwell appears in 38.05% of qualified AI answers, but it converts that presence into a valid recommendation in only 23.72% of cases and into a first-position recommendation in 0.53%. The gap between being mentioned and being chosen is where buyer decisions are lost.

Presence alone is not enough. The benchmark shows that Amwell is known to AI systems but rarely placed at the front of the recommendation set, particularly on the two highest-volume platforms. The next move is targeted correction of the prompt, page, and citation layers that determine whether Amwell is named first when a buyer asks an AI system which online doctor to use.

Core Metrics

Sentiment Score

Questions This Section Answers

• How should Amwell's 73 neutral mentions be interpreted compared to its positive recommendations?
• Why is share of voice not a reliable measure of Amwell's AI recommendation strength?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Amwell in October 2026: (142 × 1 + 73 × 0 + 0 × -1) / 215 = 0.6605.

This matters because unclassified mention counts are misleading. A brand that appears in 215 answers sounds strong until the mentions are separated into positive recommendations, neutral references, and cautionary notes. Amwell's 215 mentions break down into 142 positive and 73 neutral, with no negative mentions. That is a clean framing profile, but the 73 neutral mentions are references, not endorsements, and they should not be counted as recommendation wins.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because the difference between being named as a preferred option and being listed as a background reference is the difference between winning and losing the buyer shortlist.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Amwell's AI recommendation visibility in the Online Doctors category for October 2026. It is not a client implementation case study and does not reflect CiteWorks Studio client work.
2. The reporting window is October 2026, with comparisons to July 2026, August 2026, and September 2026 where the benchmark provides them.
3. Six AI search and assistant surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Overviews, and Google AI Mode. All six were represented in the October 2026 qualified observation set.
4. The October 2026 benchmark began with 800 prompt-surface observations and produced 565 qualified observations after qualification. Brand-level percentages use the 565 qualified observations as the public denominator.
5. The competitor universe contains ten tracked brands: Amwell, Doctor on Demand, HealthTap, K Health, Lemonaid Health, LiveHealth Online, MDLive, plushcare, Sesame, and Teladoc Health.
6. Three public high-intent clusters were defined: C01, Best Online Doctors and Top Telehealth Services; C02, Online Doctor Comparisons and Alternatives; and C03, Online Doctor Pricing, Cost and Insurance. Only C01 returned sufficient qualified observations in October 2026.
7. Stage 0 extraction retains the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources. Source presence is evidence about the information environment and is not automatically proof that the source caused the recommendation.
8. A mention is counted when Amwell appears anywhere in a qualified AI response, regardless of placement or framing.
9. A valid recommendation is counted when Amwell receives a positive valid recommendation with a rank between 1 and 10. Neutral references, cautionary mentions, and listed-only appearances are not counted as valid recommendations.
10. The benchmark tracks PlushCare and plushcare as separate brand strings in October 2026. The lowercase plushcare string appears as a distinct entry from the casing used in prior months. This report treats them as the benchmark does and does not resolve the identifier question.
11. The Pricing and Value and Multi-Brand Comparison clusters returned zero qualified observations across the full series. Commercial questions about price competitiveness, value positioning, and head-to-head comparison outcomes cannot be answered from the current public benchmark.
12. Month-over-month movement identifies changes worth investigating. It does not by itself establish the cause of those changes. Movements in coverage or placement reflect observed changes in AI-generated outputs across the tested surfaces during the measurement window.

See How AI Is Recommending Your Brand

The public benchmark shows where Amwell stands in AI-generated online doctor recommendations. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and citation sources that determine whether Amwell is named first when buyers ask AI systems which online doctor to use.